Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy tested to boost stomach cancer fight before surgery

NCT ID NCT07059299

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing whether combining a newer immunotherapy drug (tislelizumab) with standard chemotherapy (FLOT) is safe and tolerable when given before surgery for certain stomach and esophagus cancers. The goal is to see if giving more chemotherapy before surgery, instead of splitting it before and after, is a better approach for patients who often struggle with post-surgery treatment. This study will enroll 18 adults with locally advanced but removable cancer to check for safety and early signs of effectiveness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hämatologisch-Onkologische Praxis Eppendorf (hope)

    NOT_YET_RECRUITING

    Hamburg, 20249, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Klinikum rechts der Isar München der TU München

    RECRUITING

    München, 81675, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF)

    RECRUITING

    Frankfurt, 60488, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsklinikum Leipzig

    NOT_YET_RECRUITING

    Leipzig, 04103, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL ADENOCARCINOMA ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA GASTRIC ADENOCARCINOMA NEOADJUVANT THERAPY RESECTABLE ESOPHAGOGASTRIC ADENOCARCINOMA